HET0016

HET0016 is a potent and selective 20-hydroxyeicosatetraenoic acid (20-HETE) synthase inhibitor, with IC50 values of 17.7 nM, 12.1 nM and 20.6 nM for recombinant CYP4A1-, CYP4A2- and CYP4A3-catalyzed 20-HETE synthesis, respectively. HET0016 also is a selective CYP450 inhibitor, which has been shown to inhibit angiogenesis and tumor growth[1][2].

Product Specifications

CAS Number

[339068-25-6]

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

Cytochrome P450

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/het0016.html

Purity

99.69

Solubility

DMSO : 5 mg/mL (ultrasonic)

Smiles

CCCCC1=CC=C(C(C)=C1)/N=C/NO

Molecular Formula

C12H18N2O

Molecular Weight

206.28

Precautions

H315, H319, H335

References & Citations

[1]Seki T, et al. Cytochrome P450 4A isoform inhibitory profile of N-hydroxy-N'- (4-butyl-2-methylphenyl) -formamidine (HET0016), a selective inhibitor of 20-HETE synthesis. Biol Pharm Bull. 2005 Sep;28 (9) :1651-4.|[2]Borin TF, et al. HET0016 decreases lung metastasis from breast cancer in immune-competent mouse model. PLoS One. 2017 Jun 13;12 (6) :e0178830.|[3]Liu Y, et al. The protective effect of HET0016 on brain edema and blood-brain barrier dysfunction after cerebral ischemia/reperfusion. Brain Res. 2014 Jan 28;1544:45-53.